转移性胰腺癌未接受系统治疗的人群特征与预后因素
该全国性队列纳入2015-2023年荷兰癌症登记处13756例同步转移性胰腺癌患者,72%未接受系统治疗。未治疗独立预测因素包括高龄、体能状态差、mGPS 1-2、Charlson合并症指数≥2及低社会经济地位;未治疗者中位总生存42天,治疗者213天。
要点
- 72%的同步转移性胰腺癌患者未接受系统治疗,中位总生存仅42天。
- 未治疗独立预测因素包括高龄、PS>0-1、mGPS 1-2、合并症指数≥2及低社会经济地位。
- 未治疗主要原因为患者及家属偏好(39%),其次为合并症或体能状态受损(31%)。
核心结论
- 绝大多数同步转移性胰腺癌患者未接受系统治疗,主要基于患者偏好和健康状况。
- 研究强调需个体化预后评估及循证共享决策。
研究设计与样本
- 基于荷兰癌症登记处的全国性人群研究,纳入2015-2023年13756例同步转移性胰腺癌患者。
- 采用多因素logistic回归、Kaplan-Meier生存曲线及多因素多项式回归(以生存时间第25和75百分位分析)。
主要发现
- 13756例转移性胰腺癌患者中72%未接受系统治疗。
- 未接受系统治疗者中位总生存42天,接受系统治疗者213天。
- 未治疗原因主要为患者及家属偏好(39%),其次为患者因素如合并症或体能状态受损(31%)。
- 未治疗患者中50%体能状态良好(WHO 0-1),当未治疗基于偏好时该比例为68%。
- 未治疗患者中,高龄、PS 3-4、mGPS 1-2、仅腹膜或多器官转移与更差生存相关,仅肺和仅淋巴结转移与更好总生存相关。
关键数值与推荐
- 未接受系统治疗的独立预测因素:年龄增加、WHO PS>0-1、mGPS 1-2、Charlson合并症指数≥2、低社会经济地位。
临床怎么用
- 对转移性胰腺癌患者应结合年龄、体能状态、合并症、mGPS及转移部位进行个体化预后评估。
- 临床决策中应重视患者及家属偏好,开展循证共享决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with metastatic pancreatic cancer (mPAC) may not receive systemic treatment (ST), yet determinants of not receiving ST in this setting remain poorly defined. This nationwide study aims to identify clinical and demographic factors associated with not receiving ST in patients with mPAC. METHOD: Patients with synchronous mPAC from the Netherlands Cancer Registry were included (2015-2023). Multivariable logistic regression, Kaplan Meier survival curves and multivariable multinomial regression using percentile 25 and 75 of survival time were performed. RESULTS: Among 13,756 patients with mPAC, 72% did not receive ST. Independent predictors of no-ST included increasing age, worse WHO PS (>0-1), modified Glasgow Prognostic Score (mGPS) 1-2, Charlson Comorbidity index ≥ 2, and low socioeconomic position. Reason for not receiving ST was mostly due to patient and family preference (39%), followed by patient factors (31%, comorbidity or impaired performance status (PS)). Half of patients not receiving ST had a good PS (WHO 0-1) (50%), while this was 68% when not receiving ST was based on preference. Median overall survival was 42 days (no-ST) versus 213 days (ST). In patients with no-ST, older age, PS of 3-4, mGPS 1-2, and peritoneum only or multiple organ sites with metastases were associated with worse survival, whereas lung- and lymph node-only metastases were associated with better overall survival. CONCLUSION: In this nationwide study, a large majority of patients with synchronous mPAC did not receive ST, mostly based on preference and patient health factors. Our findings highlight the need for individualized prognostic assessment, and evidence-based shared decision-making.
引用
- Broekman THT, Mackay TM, de Vos-Geelen J, et al. Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study. Eur J Cancer. 2026. PMID: 42447514. doi:10.1016/j.ejca.2026.116943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。